Cargando…

Pharmacological Inhibition of PP2A Overcomes Nab-Paclitaxel Resistance by Downregulating MCL1 in Esophageal Squamous Cell Carcinoma (ESCC)

SIMPLE SUMMARY: Paclitaxel-based chemotherapy has been introduced to treat esophageal squamous cell carcinoma. While its initial efficacy has been clinically established, the development of resistance is inevitable. To understand the paclitaxel resistance mechanism, we developed nanoparticle albumin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Qi, Wang, Herui, Jiang, Dongxian, Xu, Chen, Cui, Jing, Zhang, Qi, Wang, Haixing, Huang, Jie, Su, Jieakesu, Wu, Gen Sheng, Zhuang, Zhengping, Hou, Yingyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507542/ https://www.ncbi.nlm.nih.gov/pubmed/34638252 http://dx.doi.org/10.3390/cancers13194766

Ejemplares similares

High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients
por: Song, Qi, et al.
Publicado: (2017)

SOX2 amplification and chromosome 3 gain significantly impact prognosis in esophageal squamous cell carcinoma
por: Wang, Xin, et al.
Publicado: (2021)

PMS2 Expression With Combination of PD-L1 and TILs for Predicting Survival of Esophageal Squamous Cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2022)

Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy
por: Jiang, Dongxian, et al.
Publicado: (2023)

The prognostic value of EGFR overexpression and amplification in Esophageal squamous cell Carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2015)

Chromosomal and Genomic Variations in Esophageal Squamous Cell Carcinoma: A Review of Technologies, Applications, and Prospections
por: Song, Qi, et al.
Publicado: (2017)

Increased MET gene copy number negatively affects the survival of esophageal squamous cell carcinoma patients
por: Wang, Yanqiu, et al.
Publicado: (2019)

The prognostic significance of MCL1 copy number gain in esophageal squamous cell carcinoma
por: Xu, Chen, et al.
Publicado: (2017)

Comparison of the prognostic difference between ypTNM and equivalent pTNM stages in esophageal squamous cell carcinoma based on the 8th edition of AJCC classification
por: Jiang, Dongxian, et al.
Publicado: (2020)

Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma
por: Yang, Yafan, et al.
Publicado: (2023)

nab-Paclitaxel for the treatment of pancreatic cancer
por: Kim, George
Publicado: (2017)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Kokubu, Hiraku, et al.
Publicado: (2023)

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated With Better Patient Outcome
por: Huang, Jie, et al.
Publicado: (2021)

Tumour infiltrating lymphocytes correlate with improved survival in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2017)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Wan, Rui, et al.
Publicado: (2023)

Independent prognostic role of PD-L1 expression in patients with esophageal squamous cell carcinoma
por: Jiang, Dongxian, et al.
Publicado: (2016)

ATF3 suppresses ESCC via downregulation of ID1
por: Li, Jian, et al.
Publicado: (2016)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Neoadjuvant nab-paclitaxel in the treatment of breast cancer
por: Ueno, Naoto T., et al.
Publicado: (2016)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Prognostic value of visual residual tumour cells (VRTC) for patients with esophageal squamous cell carcinomas after neoadjuvant therapy followed by surgery
por: Wang, Xingxing, et al.
Publicado: (2021)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Identification of clinical prognostic features of esophageal cancer based on m6A regulators
por: Wang, Huimei, et al.
Publicado: (2022)

Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer
por: Al-Hajeili, Marwan, et al.
Publicado: (2014)

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
por: Alvarez, R, et al.
Publicado: (2013)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Singh, Harjinder, et al.
Publicado: (2023)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong, Yuan, et al.
Publicado: (2020)

FGFR inhibitors combined with nab-paclitaxel - A promising strategy to treat non-small cell lung cancer and overcome resistance
por: Ma, Feng, et al.
Publicado: (2023)

MEX3A is upregulated in esophageal squamous cell carcinoma (ESCC) and promotes development and progression of ESCC through targeting CDK6
por: Wei, Lei, et al.
Publicado: (2020)

Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression
por: Woo, S M, et al.
Publicado: (2014)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
por: Yamamoto, Yutaka, et al.
Publicado: (2011)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Vishnu, Prakash, et al.
Publicado: (2011)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, Nab-Paclitaxel)
por: Blais, Normand, et al.
Publicado: (2014)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca, Rossella, et al.
Publicado: (2018)

Nab-paclitaxel - Third-line chemotherapy in advanced gallbladder cancer
por: Patel, Amol, et al.
Publicado: (2020)

Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors
por: Munster, Pamela N., et al.
Publicado: (2022)

The role of copper transporter ATP7A in platinum-resistance of esophageal squamous cell cancer (ESCC)
por: Li, Zhuang-hua, et al.
Publicado: (2016)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pm5dtrn4bso86b5j8igcp0l0po